These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27668546)

  • 1. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
    McCarberg BH; Kopecky EA; O'Connor M; Marseilles A; Varanasi RK; Thompson C; Fleming AB
    Curr Med Res Opin; 2016 Dec; 32(12):1975-1982. PubMed ID: 27668546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxycodone DETERx
    Lamb YN; Garnock-Jones KP; Keam SJ
    Drugs; 2016 Dec; 76(18):1759-1769. PubMed ID: 27832472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxycodone DETERx
    Gudin J
    Pain Ther; 2016 Dec; 5(2):171-186. PubMed ID: 27873179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
    Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Human Abuse Potential of Oxycodone DETERx
    Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
    J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
    Gudin J
    J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.
    McDonald AM; Spencer SA; Willey CD; Bonner JA; Dobelbower MC; Swain TA; Nabell L; McCammon S; Carroll WR; McGwin G; Bhatia S; Yang ES
    Support Care Cancer; 2021 Jan; 29(1):263-269. PubMed ID: 32350670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
    Webster LR; Kopecky EA; Smith MD; Fleming AB
    Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxycodone extended release capsules for the treatment of chronic pain.
    Mercadante S
    Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Drug Release After Crushing: Evaluation of Xtampza
    Mayock SP; Saim S; Fleming AB
    Clin Drug Investig; 2017 Dec; 37(12):1117-1124. PubMed ID: 28940174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
    Argoff CE; Kopecky EA
    Curr Med Res Opin; 2014 Dec; 30(12):2543-59. PubMed ID: 25244248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres.
    Fleming AB; Scungio TA; Grima MP; Mayock SP
    J Opioid Manag; 2016; 12(1):57-65. PubMed ID: 26908304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.